Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318584 · ClinicalTrials.gov registry record · Phase 2
Cefotetan Therapy for Escherichia Coli Infections
A Phase 2 study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT07318584: Clinical Trial Phase 2 study, sponsored by Oregon Health and Science University.
NCT07318584 is a Phase 2 study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07318584, a Phase 2 study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.
Primary Outcome
Absence of death, recurrent E. coli, bacteremia, or need for antibiotic treatment for recurrent E.coli genitourinary infection.
Interventions
- DRUG Cefotetan
- DRUG Carbapenems
- DRUG Beta Lactam Antibiotics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
What is known before NCT07318584 opens enrollment
NCT07318584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 3 interventions - of which Cefotetan is the first listed.
NCT07318584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07318584 about?
NCT07318584 is a clinical study titled "Cefotetan Therapy for Escherichia Coli Infections". This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum conce...
What is the current status of trial NCT07318584?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2026-03. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07318584?
The interventions under investigation include: Cefotetan (DRUG), Carbapenems (DRUG), Beta Lactam Antibiotics (DRUG).
Who is sponsoring clinical trial NCT07318584?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07318584's enrollment target sits among peer trials
84 822nd of 2000 higher than 1,173 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia